Sage Journals: Discover world-class research

Abstract

Objective: To determine the potential effectiveness of a behavioural weight control programme including physical exercise in the prevention of antipsychotic-induced weight gain and associated comorbid conditions in outpatients with schizophrenia and mood disorders.

Methods: A prospective, comparative, open and naturalistic study was carried out for a total of 110 patients with schizophrenia, schizoaffective or bipolar disorders (DSM-IV), on treatment with atypical antipsychotics. Of these, 59 patients participated in an 18 month weight control programme that included an educational activity about dietary and physical activity counselling as well as a structured, supervised, facility-based exercise programme. The control group consisted of 51 patients with the same baseline characteristics who did not receive the clinical programme. Anthropometric measurements, plasma lipid–lipoprotein profile, and fasting plasma glucose concentrations were assessed at 11 time-points over the study. In addition, serum concentrations of prolactin, thyrotropin-stimulating hormone (TSH), and glycated haemoglobin (HbA_1c) were assessed at four time-points. Finally, the Clinical Global Impression scale (CGI), the Brief Psychiatric Rating Scale (BPRS) and the Short Form (SF)-36 Health Survey were used.

Results: The adherence rate of patients was 85%, both in the active and in the control group. Whereas the control group experienced a significant increase in bodyweight (4.1%), body mass index (BMI; 5.5%) and waist circumference (WC; 4.2%), the active group significantly reduced their bodyweight (−3.5%), BMI (−4.4%), and WC (−4.6%) at the study end-point. In addition, a significant increase in low-density lipoprotein (LDL)-cholesterol (14.8%) and in triglyceride concentrations (12.3%) was observed at month 18 in the control group. In contrast, high-density lipoprotein-cholesterol (HDL) significantly increased (21.4%), and LDL cholesterol (−13.7%), triglycerides (−26.2%), total cholesterol (−12.1%), fasting glucose concentrations (−12.0%), and HbA_1c (−11.4%) significantly decreased compared to baseline in the active group. No significant changes were observed regarding serum concentrations of prolactin and TSH during the study. In regard to the changes observed in psychological measures, no between-group differences were seen in the clinical ratings of CGI and BPRS. However, the SF-36 showed that physical health was improved only for subjects in the active group at months 12 and 18 compared to baseline (p<0.05), and mental health was significantly improved for both groups at months 12 and 18 compared to baseline.

Conclusion: Bodyweight and metabolic risk profile in patients receiving atypical antipsychotic medications can be effectively managed with a weight control programme including physical activity.

Keywords

atypical antipsychotics bodyweight metabolic profile mood disorders schizophrenia

Antipsychotic drugs have been known for years to induce weight gain [1] and stimulate appetite [2]. In the last 15 years novel atypical antipsychotics have been developed that possess advantages over older typical agents in terms of both reduced side-effects (particularly reduced motoric extrapyramidal side-effects) and various enhanced therapeutic effects (greater efficacy against negative symptoms, reduction of suicidality and efficacy in some treatment-resistant patients who do not respond to older antipsychotic drugs) [3]. These advantageous properties have led to atypical antipsychotics being widely considered the drugs of first choice for the treatment of schizophrenia [4] and are now considered major therapeutic tools in the management of mood disorders [5]. In contrast, the relative effectiveness of second-generation antipsychotic drugs as compared with that of older agents have been addressed only recently in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study [6]. That large-scale study found that only olanzapine was the most effective in terms of rates of discontinuation, although this atypical antipsychotic drug was associated with greater weight gain and increases in measures of glucose and lipid metabolism [6]. Indeed, second-generation antipsychotics may induce marked weight gain associated with abdominal obesity [7] and enhanced adiposity [8], which causes expected increases in morbidity and mortality, as well as reduced quality of life [9], and interferes with medication compliance [10], leading to relapse [11]. Thus, weight gain and metabolic disturbance encountered with these agents have emerged as a major concern for clinicians nowadays [12–19], at the same time as we face an obesity epidemic.

The ability of antipsychotic drugs to induce weight gain is of particular significance in people with schizophrenia and mood disorders who are typically overweight [20, 21] and who have enhanced levels of visceral fat [22, 23]. Typically, weight gain seen with the newer antipsychotics increases over a number of months of treatment and ultimately reaches a plateau that may vary between drugs [24–27]. Although atypical antipsychotic agents are the most effective pharmacological tools in the management of many psychotic and affective disorders, the choice of such a medication should be individualized to each patient, with consideration of the risks and benefits of treatment [28–30]. In this respect, screening and monitoring of weight, diet, and exercise in patients with mood and psychotic disorders will help to limit or eliminate weight gain and obesity as potential added metabolic risk factors [31–34]. Indeed, patients with schizophrenia and mood disorders should be screened regularly, especially in the presence of other risk factors for type 2 diabetes [35].

While treating obesity in the general population has proven to be a challenge, the challenge may be even greater for those who have gained weight in relation to a mental disorder and its pharmacological treatment. It might be indeed extremely difficult for some chronically and severely mentally ill patients who require antipsychotic treatment to eat less and exercise more when their treatment increases appetite and produces fatigue and sedation, and their illnesses decrease motivation and limit social interactions and activities. Moreover, their typically strained financial resources and social circumstances often limit their access to low-calorie foods and preclude membership in health clubs, access to exercise equipment, and dietary counselling or education. Such general health-promoting activities are rarely provided in contemporary psychiatric clinical services or covered by health insurance programmes for psychiatric illness, despite support for their integration into mental health services [36].

Accordingly, the present study aimed to document the effectiveness of a behavioural weight control programme including physical exercise in the prevention of antipsychotic-induced weight gain and associated comorbid conditions in outpatients with schizophrenia and mood disorders. Only a small number of studies have examined behavioural intervention programmes including both diet and exercise counselling in this patient population [37–41]. They provided the best evidence for small weight reductions among patients with schizophrenia over short time intervals [37] or considered the long-term success of these interventions [38–41]. However, such a conclusion is tempered by some design flaws and the small sample sizes used in those studies. Owing to the fact that antipsychotic drugs are associated with weight gain and metabolic dysregulation and because little is known about the management of this problem, we thus sought to examine the potential effectiveness of a behavioural weight control programme over an 18 month period by comparing its outcome to the status of control subjects who were also clinically supervised over the same period of time.

Methods

Subjects

Subjects fulfilling the following criteria were eligible for participation: ≥18 years of age; DSM-IV diagnosis of schizophrenia, schizoaffective or bipolar disorder; sedentary or moderately active (i.e. <3 h of physical activity/week); and in current treatment with an atypical antipsychotic drug alone or in combination with other psychotropic agents. Patients presenting medical contraindications to follow a physical activity programme or those having previously been enrolled in a similar clinical programme were excluded of the present study. A total number of 130 subjects were recruited through the outpatients followed in the Psychiatric Departments of Hôpital de l'Enfant-Jésus and Centre Hospitalier Robert-Giffard (Quebec, Canada). Among those subjects, 70 were included in the active group (experimental group) and 60 were considered as controls. The subjects were allocated to a 1:1 ratio after we decided to include a control group, explaining the different sample sizes. All of these subjects continued their habitual psychiatric follow up with their psychiatrist. The subjects included in the control group presented the same baseline characteristics and constituted the comparison group (Table 1). The effectiveness of this behavioural weight control programme was thereby evaluated by the addition of a clinical programme over an 18 month period and by comparing the outcomes obtained to the outcomes of habitual psychiatric outpatients who were not implicated in such a programme but who were supervised according to usual clinical practices. All subjects provided written informed consent after review and approval of the study by the Ethical Committee of the Centre Hospitalier Affilié Universitaire de Québec.

Table 1.

Baseline patient characteristics

	Control group (n = 51)		Active group (n = 59)
Variable^†	n	%	n	%
Gender
Male	26	51	31	53
Female	25	49	28	47

Ethnicity
White	51	100	59	100

Diagnosis
Schizophrenia	15	29	19	32
Schizoaffective disorder	17	33	19	32
Bipolar disorder	19	37	21	36

Comorbid conditions
Obesity	24	45	28	47
Diabetes	6	12	8	14
Hypertension	9	18	10	17
Hypercholesterolaemia	10	20	11	19

Other risk factors
Smoking	30	59	34	58

Atypical antipsychotic profile
Clozapine	5	10	6	10
Olanzapine	35	69	39	66
Risperidone	5	10	7	12
Quetiapine	6	12	7	12

^†Frequencies are not significantly different between groups.

Project overview

This prospective, comparative, open and naturalistic study aimed to determine the potential effectiveness of a behavioural weight control programme in the prevention of antipsychotic-induced weight gain and associated comorbid conditions in outpatients with schizophrenia and mood disorders. The patients included in the active group (nutritional recommendations and physical exercise) were compared to those who were not included in this clinical programme. In this regard, the programme offered to the experimental group included a small group educative activity about dietary and physical activity counselling. This educative activity of 90 min length was given once at the beginning of the study for the active group and was delivered by a nutritionist and a psychiatric nurse. The focus here was that the patient understands the role of nutrition and exercise as a vital therapeutic goal in preventing many risk factors. The Canada's food guide to healthy eating was a useful tool for this nutrition education counselling [42]. In addition, the active group was involved in a structured, supervised, facility-based exercise programme in a small gymnasium of the Hôpital de l'Enfant-Jésus. A kinesiologist supervised small groups (8–10 subjects) who were devoted to exercise sessions including cardiovascular workouts on treadmills and stationary cycles. Strength-training exercises included use of free weights and resistance bands as well as flexibility and balance drills. Music was used to maintain enthusiasm for exercise sessions. Rates of perceived exertion and heart rate were closely monitored. Special attention was given to subjects with medication-related impaired balance and coordination. This individualized fitness training was performed for 60 min twice a week over the 18 month period.

Assessments

Patients were evaluated at 12 study visits: screening visit for eligibility, baseline visit within 1 month of the initial screening visit, and at months 1, 2, 3, 4, 5, 6, 8, 10, 12 and 18. Screening procedures included physical and mental examination, 12-lead electrocardiogram and medical history. During the other visits the measurements described in the following section were performed in each subject.

Anthropometric measurements

Bodyweight, height, and waist circumference (WC) were measured according to standardized procedures recommended at the Airlie Conference [43]. Body mass index (BMI) was calculated as bodyweight divided by height squared (kg m⁻²).

Biochemistry

Blood samples were collected from an antecubital vein into vacutainer tubes containing ethylenediamine tetra-acetic acid (EDTA) after a 12 h overnight fast for the determination of plasma lipids and lipoproteins. Plasma was separated immediately after blood collection by centrifugation at 850 g for 10 min at 4°C. Plasma cholesterol and triglyceride concentrations were determined enzymatically in plasma lipoprotein fractions using a Technicon RA-500 automated analyzer (Bayer, Tarrytown, NY, USA) and enzymatic reagents were obtained from Randox (Crumlin, UK). Plasma lipoprotein fractions (low-density and high-density lipoprotein; LDL and HDL) were isolated using previously described procedures [44]. In addition, serum concentrations of prolactin, thyrotropin-stimulating hormone (TSH), and glycated haemoglobin (HbA_1c) were performed by standardized procedures routinely used at the Centre Hospitalier Robert-Giffard (only at baseline and at months 6, 12, and 18 for these three variables). Finally, fasting plasma glucose concentrations were enzymatically determined using the technique of Richterich and Dauwalder [45].

Psychological assessments

The Clinical Global Impression scale (CGI) was used to describe the patient's overall clinical state as a global impression by the psychiatrist [46]. Both the CGI-Severity (CGI-S) and the CGI-Global Improvement (CGI-I) scales were used in the present study. The CGI-S assesses the clinician's impression of the patient's current illness state and gives a score ranging from 1 (disease-free) to 7 (greatest possible severity), whereas the CGI-I assesses the patient's improvement or worsening since the start of the study and gives a score ranging from 1 (very much improved) to 7 (very much worse). In addition, the psychopathology state of subjects was determined with the Brief Psychiatric Rating Scale (BPRS) [47]. The BPRS is a Likert-type scale composed of 18 items that are evaluated by the interviewer, in which each item gives a score ranging from 0 (absence of symptom) to 7 (extreme severity). Finally, the Short Form (SF)-36 Health Survey was used as a generic measure of health status [48]. It is a multipurpose, short-form health survey that contains 36 questions and yields an eight-scale profile of scores as well as a summary of physical and mental measures. High scores are associated with a good health status. Both the BPRS and the SF-36 Health Survey were used only at baseline and at months 12 and 18. Furthermore, it is to be noted that the clinician ratings of psychopathology were blind to control or intervention status.

Statistical analysis

Mean, standard deviation, and frequency were calculated. A χ² test was used for comparison of frequencies between the control and active group. An analysis of variance (ANOVA) for repeated measures was performed to assess the effect of sex as well as the sex × treatment (control vs physical activity programme) interactions on all dependent variables. Because there was no sex effect or sex × treatment interaction, we combined the data for both sexes in order to improve clarity and statistical power. An ANOVA for repeated measures was used to assess the differences over time. A Tukey's honestly significant difference post-hoc test was then performed in order to contrast mean differences. Adjustment for type of drug, dose of drug or duration of drug therapy had no meaningful effect on the outcomes. Data are given as mean ± SD unless otherwise noted. Statistical significance was set at p < 0.05. All statistical analyses were performed using JMP version 3.2.2 (SAS Institute, Cary, NC, USA).

Results

Participants

Of 70 enrolled subjects in the active group, 11 dropped out for many reasons (patient request, n = 4; loss to follow up, n = 3; difficulties with scheduling, n = 3; or mortality, n = 1). Similarly, the control group was first constituted of 60 subjects, of whom nine dropped out for the same reasons (patient request, n = 3; loss to follow up, n = 2; difficulties with scheduling, n = 3; or mortality, n = 1). In this regard the adherence rate of patients was 85%, both in the active and in the control group. In addition, the subjects included in the exercise programme were in general compliant with this clinical intervention and particularly by their capacity to reach a minimal commitment of six sessions every 4 weeks. The baseline characteristics of participants were not significantly different between the two groups, as shown in Table 1. The mean age of subjects was 36.1±6.1 years and 35.3±5.2 years in the active and control group, respectively. Moreover, the patients did not present significant mean difference between groups regarding the duration of drug therapy before study entry. They had taken the current primary antipsychotic agent for an average of 2.63±1.68 years and 2.68±1.61 years for the active and control group, respectively. The duration of secondary psychotropic medications before study entry was similar (2.42±2.34 years vs 2.36±2.82 years for the active and control group, respectively).

Changes in anthropometric variables

Figure 1 presents changes in bodyweight over the study in the active and control groups, whereas Table 2 shows values over time and changes from baseline for anthropometric measurements. Whereas the control group experienced a significant increase in bodyweight (4.1%), BMI (5.5%) and WC (4.2%), the active group reduced significantly its bodyweight (−3.5%), BMI (−4.4%), and WC (−4.6%) by the study end-point. Therefore, the changes observed at the study end-point for these three anthropometric variables differed substantially between the two groups: bodyweight (difference of 6.7 kg, p < 0.01), BMI (difference of 3.2 kg m⁻², p < 0.01) and WC (difference of 9.3 cm, p < 0.01).

Figure 1.

Mean changes in bodyweight over the study in the control (n = 51) and active (n = 59) groups. Vertical bars, standard errors. ∗∗p < 0.01.

Table 2.

Anthropometric measurements

	Control group (n = 51)		Active group (n = 59)
Variable	Mean ± SD	Change	Mean ± SD	Change
Bodyweight (kg)
Baseline	85.2±18.0		87.5±19.9
Month 3	86.7±17.5		86.9±19.7
Month 6	87.0±18.6		85.5±17.8
Month 8	87.0±20.0		85.4±17.7
Month 10	87.5±20.4		85.3±18.0
Month 12	87.7±16.9		85.2±18.8
Month 18	88.8±12.3	+3.6∗∗	84.4±18.2	−3.1∗∗ ^##

BMI (kg m⁻²)
Baseline	31.1±5.9		31.5±5.5
Month 3	31.6±5.8		31.2±5.4
Month 6	31.7±5.7		30.9±5.6
Month 8	31.9±5.8		30.8±5.8
Month 10	32.2±6.0		30.7±6.0
Month 12	32.4±6.5		30.5±6.2
Month 18	32.9±6.7	+1.8∗∗	30.1±6.0	−1.4∗ ^##

WC (cm)
Baseline	103.3±17.4		104.5±15.9
Month 3	104.7±16.5		102.8±15.0
Month 6	105.0±15.8		101.9±15.8
Month 8	105.5±15.7		101.6±15.3
Month 10	105.9±16.1		101.3±15.6
Month 12	106.5±16.7		101.1±16.1
Month 18	107.8±15.8	+4.5∗∗	99.7±15.7	−4.8∗∗ ^##

BMI, body mass index; WC, waist circumference; ∗Significantly different from baseline, p < 0.05, ∗∗p < 0.01; ^##Significantly different from control group, p < 0.01.

Changes in biochemistry

As shown in Table 3, an opposite trend was observed between the two groups regarding the lipid–lipoprotein profile and fasting glucose concentrations over time as well as for changes from baseline. Indeed, a significant increase in LDL-cholesterol (14.8%) and in triglyceride concentrations (12.3%) was observed at month 18 for the control group. In contrast, HDL-cholesterol significantly increased (21.4%), and LDL cholesterol (−13.7%), triglycerides (−26.2%), total cholesterol (−12.1%), and fasting glucose concentrations (−12.0%) significantly decreased compared to baseline in the active group. In regard to the variations observed between the two groups at study end-point, significant mean differences were observed as follows: total cholesterol (difference of 1.00 mmol L⁻¹, p < 0.01), LDL-cholesterol (difference of 1.02 mmol L⁻¹, p < 0.01), HDL-cholesterol (difference of 0.33 mmol L⁻¹, p < 0.05), triglycerides (difference of 0.88 mmol L⁻¹, p < 0.05), and fasting glucose concentrations (difference of 0.79 mmol L⁻¹, p < 0.05). No significant changes were observed regarding serum concentrations of prolactin and TSH over the study, whereas HbA_1c significantly decreased (−11.4%) compared to baseline in the active group (data not shown).

Table 3.

Plasma lipid–lipoprotein profile and fasting glucose

	Control group (n = 51)		Active group (n = 59)
Variable	Mean ± SD	Change	Mean ± SD	Change
Cholesterol (mmol L⁻¹)
Baseline	5.30±0.95		5.38±1.13
Month 3	5.41±1.13		5.14±1.23
Month 6	5.45±1.09		5.00±1.31
Month 8	5.47±0.95		4.92±1.15
Month 10	5.49±0.96		4.88±0.94
Month 12	5.56±0.88		4.83±0.88
Month 18	5.65±1.01	+0.35	4.73±0.97	−0.65∗ ^##

LDL-Chol (mmol L⁻¹)
Baseline	3.22±0.84		3.35±0.99
Month 3	3.34±0.83		3.22±1.09
Month 6	3.44±0.87		3.15±1.02
Month 8	3.57±0.98		3.05±1.09
Month 10	3.58±0.92		3.02±0.89
Month 12	3.66±0.98		2.98±0.96
Month 18	3.78±0.97	+0.56∗	2.89±0.85	−0.46∗ ^##

HDL-Chol (mmol L⁻¹)
Baseline	1.06±0.26		1.03±0.32
Month 3	1.05±0.27		1.11±0.79
Month 6	1.09±0.28		1.16±0.36
Month 8	1.09±0.27		1.16±0.29
Month 10	1.10±0.24		1.18±0.41
Month 12	1.08±0.35		1.22±0.33
Month 18	1.01±0.30	−0.05	1.31±0.39	+0.28∗ ^#

TG (mmol L⁻¹)
Baseline	2.14±0.69		2.21±1.11
Month 3	2.22±0.98		2.09±1.01
Month 6	2.27±1.17		2.00±1.05
Month 8	2.32±0.89		1.97±0.78
Month 10	2.31±0.85		1.90±0.70
Month 12	2.37±0.82		1.81±0.85
Month 18	2.44±15.8	+0.30∗	1.63±15.7	−0.58∗ ^##

Glucose (mmol L⁻¹)
Baseline	6.22±0.88		6.33±2.59
Month 3	6.21±1.08		6.01±1.30
Month 6	6.16±1.08		5.86±1.11
Month 8	6.17±0.72		5.81±1.04
Month 10	6.28±0.90		5.76±1.01
Month 12	6.21±1.03		5.71±0.89
Month 18	6.25±0.54	+0.03	5.57±0.74	−0.76∗ ^#

Chol, cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides; ∗Significantly different from baseline, p < 0.05; ^#Significantly different from control group, p < 0.05, ^##p < 0.01.

Changes in psychological measures

No between-group differences were seen in the clinical ratings of CGI-S and CGI-I during the study (Figure 2). Nevertheless, mean CGI-S scores were significantly lower for both groups at months 3, 6, 8, 10, 12 and 18 (p < 0.05) compared to baseline, and particularly for the active group at month 18 (p < 0.01). With respect to CGI-I scores, only the active group presented significantly lower mean scores at months 12 and 18 compared to baseline (p < 0.05). No significant difference was observed between the two groups (Figure 3) regarding the psychiatric status measured with the use of BPRS. However, both groups were significantly improved at months 12 and 18 (p < 0.05) compared to baseline.

Figure 2.

Mean scores for Clinical Global Impressions scales for (a) severity (CGI-S) and (b) global improvement (CGI-I). Vertical bars, standard errors. ∗significantly different from baseline, p < 0.05; ∗∗p < 0.01. Values within each mean score are not significantly different. Control group, n = 51; active group, n = 59.

Figure 3.

Mean scores for the Brief Psychiatric Rating Scale (BPRS). Vertical bars, standard errors. ∗significantly different from baseline, p < 0.05. Values within each mean score are not significantly different. Control group, n = 51; active group, n = 59.

Finally, the SF-36 Health Survey was used as a tool for measuring health status (physical and mental health) and was filled out by the subjects. The results showed that physical health was improved only for subjects in the active group at months 12 and 18 compared to baseline (p < 0.05). In contrast, mental health was significantly improved for both groups at months 12 and 18 compared to baseline (p < 0.05; Figure 4).

Figure 4.

Mean scores of the two summary measures (physical and mental health) of the Short Form (SF)-36 Health Survey. Vertical bars, standard errors. ∗significantly different from baseline, p < 0.05. Values within each mean score are not significantly different. Control group, n = 51; active group, n = 59.

Discussion

The present study shows that bodyweight and metabolic risk profile in patients receiving atypical antipsychotics can be managed with a weight control programme including physical activity. Indeed, results obtained in the present study are of relevance and these findings add to the emerging view that weight gain is a major health problem associated with modern antipsychotic agents and that physical activity-based weight-control efforts in patients requiring antipsychotic treatment yield clinically promising benefits. Although the previous evidence [37–41] concurred with the results obtained here, those studies had several limitations that temper clear conclusions. In contrast, the present study included a relatively large sample size, the use of a control group and an 18 month follow up.

It is now well recognized that weight loss, even modest, has many health-related benefits. Specifically, the main argument justifying weight-reducing programmes relies on the improvement of the metabolic profile. We now refer to the term ‘metabolic syndrome’ or ‘insulin resistance syndrome’ the cluster of risk factors increasing the relative risk of type 2 diabetes and cardiovascular diseases [49]. Among the five screening variables and cut-offs proposed by the National Cholesterol Education Program–Adult Treatment Panel III [50] and used to identify subjects with the metabolic syndrome, the majority of them were improved in the active group (waist circumference, circulating levels of triglycerides and HDL-cholesterol, and fasting glycaemia), meaning that the morbidity and mortality risk profile of patients has been potentially reduced [51]. Such an outcome is not trivial because the reduction in cardiovascular risk was estimated to be 75% higher in the active compared to the control group based on available algorithms [52].

The evidence supporting the need for interventions to promote physical activity among persons with serious mental illness was recently reviewed [53]. The psychological benefits for clinical populations comes from two meta-analyses of outcomes of depressed patients that showed that effects of exercise were similar to those of psychotherapeutic interventions [54, 55]. In addition, exercise can alleviate secondary symptoms such as low self-esteem and social withdrawal [56]. Research also suggests that exercise is well accepted by people with serious mental illness [57] and is often considered one of the most valued components of treatment [58]. Thus, because individuals with serious mental illness are significantly less active than the general population [59–61], physical activity as an adjunct treatment for individuals with serious mental illness is highly desirable. Moreover, physical activity interventions are a critical component of a biopsychological approach in recovery-oriented mental health services [62].

The subjects included in the active group benefited socially from their participation in the study and reported favouring the peer support and encouragement associated with the programme. It is known that the challenge to managing obesity may be greater for those who have gained weight largely due to the use of psychotropic medications [63]. Indeed, patients who require antipsychotic treatment present a decrease in motivation and social interactions and activities. In addition, with the weight gain and metabolic effects observed in association with olanzapine (most of the patients were on olanzapine in the present study), alternative atypical agents are now available that do not carry the cardiovascular risk that this drug carries. Thus, this emphasizes the necessity for a better management of antipsychotic-induced weight gain in psychiatric patients, particularly by targeting individuals prior to weight gain.

The fact that these patients were relatively stable on medications before entry into the study means that they may have already gained a lot of weight before entering the study. Indeed, weight gain seen with the newer antipsychotics increases over a number of months of treatment and ultimately reaches a plateau [24–26]. For example, clozapine has been reported to induce weight gain that persists for as long as 46 months [27], while olanzapine-induced weight gain reaches a plateau after 10 months of treatment [26]. Nevertheless, the control group continued to gain weight, that is, 3.6 kg over the 18 month programme. This progression of weight gain, which is counter to the proposed notion of plateau, is not really surprising when one considers the fact that bodyweight/fat gain represents an unfortunate solution/adaptation to restore body homeostasis [64]. Beyond the positive energy balance explained, among other factors, by physical inactivity, we cannot exclude the possibility that bodyweight/fat gain might confer salutary effects on psychological health.

In addition to the clinical benefits obtained in the active group regarding the metabolic risk profile, changes observed in psychological measures were also an outcome of interest in the present study. In this respect, even though the clinical ratings of CGI-S, CGI-I and BPRS did not really permit observation of a difference between the two groups, these mean scores were significantly lower for both groups study compared to baseline. In addition, the behavioural weight control programme seemed to have had an impact on physical health as measured with the use of SF-36 Health Survey, albeit mental health was significantly improved for both groups at months 12 and 18 compared to baseline. These results suggest that an improvement in mental health occurred in patients of both groups over the study and that a specific effect of such a weight control programme on psychological measures was not detectable on these psychiatric scales.

In conclusion, the present findings highlight the importance of ongoing weight management intervention including physical exercise designed specifically for patients on antipsychotic treatment. The present study shows that such a programme is feasible and effective and the results obtained here are encouraging with a high rate of adherence. Nevertheless, further studies are needed to confirm the long-term success of behavioural weight control programmes in psychiatric patients and to determine the optimal modalities of such programmes.

Footnotes

Acknowledgements

This study was funded by Eli Lilly Canada. Eli Lilly Canada was not involved in any part of the study except funding.

References

1. Planansky

Heilizer

. Weight changes in relation to the characteristics of patients on chlorpromazine. J Clin Exp Psychopathol 1959; 20: 53–57.

2. Robinson

McHugh

Folstein

. Measurement of appetite disturbances in psychiatric disorders. J Psychiatr Res 1975; 12: 59–68.

3. Freedman

. Schizophrenia. N Engl J Med 2003; 349: 1738–1749.

4. Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005; 50 (Suppl 1):7S–57S.

5. Yatham

Kennedy

O'Donovan

. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7(Suppl 3)5–69.

6. Lieberman

Stroup

McEvoy

. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–1223.

7. Stedman

Welham

. The distribution of adipose tissue in female in-patients receiving psychotropic drugs. Br J Psychiatry 1993; 162: 249–250.

8. Eder

Mangweth

Ebenbichler

. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 2001; 158: 1719–1722.

9. Allison

Mackell

McDonnell

. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003; 54: 565–567.

10.

10. Weiden

Mackell

McDonnell

. Obesity as a risk factor for antipsychotic non-compliance. Schizophr Res 2004; 66: 51–57.

11.

11. Russell

Mackell

. Bodyweight gain associated with atypical antipsychotic: epidemiology and therapeutic implications. CNS Drugs 2001; 15: 537–551.

12.

12. Allison

Casey

. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62(Suppl 7)22–31.

13.

13. Baptista

Kin

Beaulieu

de Baptista

. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35: 205–219.

14.

14. Baptista

, Zarate

, Joober

. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics Curr Drug Targets 2004; 5:279–299.

15.

15. Taylor

McAskill

. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000; 101: 416–432.

16.

16. Wetterling

. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001; 24: 59–73.

17.

17. Wirshing

, Wirshing

, Kysar

. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60:358–363.

18.

18. Zimmermann

Kraus

Himmerich

Schuld

Pollmacher

. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003; 37: 193–220.

19.

19. Nasrallah

. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28(Suppl 1)83–96.

20.

20. Tardieu

Micallef

Gentile

Blin

. Weight gain profiles of new anti-psychotics: public health consequences. Obes Rev 2003; 4: 129–138.

21.

21. Consensus statement, consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596–601.

22.

22. Ryan

Flanagan

Kinsella

Keeling

Thakore

. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004; 74: 1999–2008.

23.

23. Thakore

Mann

Vlahos

Martin

Reznek

. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002; 26: 137–141.

24.

24. Martin

, Landau

, Leebens

. Risperidone-associated weight gain in children and adolescents: a retrospective chart review J Am Acad Child Adolesc Psychiatry 2000; 10:259–268.

25.

25. Jones

Basson

Walker

Crawford

Kinon

. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001; 62(Suppl 2)41–44.

26.

26. Kinon

Basson

Gilmore

Tollefson

. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92–100.

27.

27. Henderson

, Cagliero

, Gray

. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study Am J Psychiatry 2000; 157:975–981.

28.

28. Meltzer

. Putting metabolic side effects into perspective: risk versus benefits of atypical antipsychotics. J Clin Psychiatry 2001; 62(Suppl 27)35–39.

29.

29. Mauskopf

Muroff

Gibson

Grainger

. Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia. Schizophr Bull 2002; 28: 619–635.

30.

30. Poulin

Cortese

Williams

Wine

McIntyre

. Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. Can J Psychiatry 2005; 50: 555–562.

31.

31. Fox

Rotatori

Wicks

. Weight loss with psychiatric residents in a behavioral self-control program. Psychol Rep 1980; 46: 483–486.

32.

32. Knox

. A study of weight reducing diets in psychiatric in-patients. Br J Psychiatry 1980; 136: 287–289.

33.

33. Ball

Coons

Buchanan

. A program for treating olanzapine-related weight gain. Psychiatr Serv 2001; 52: 967–969.

34.

34. Cazenave

Gershon

Sletten

. Effects of caloric restriction on behavior and body weight during chlorpromazine therapy. Dis Nerv Syst 1967; 28: 519–522.

35.

35. Keck

Buse

Dagogo

. Managing metabolic concerns in patients with severe mental illness. McGraw Hill Healthcare Information Group, Edina, MN 2003.

36.

36. Richardson

Faulkner

McDevitt

Skrinar

Hutchinson

Piette

. Integrating physical activity into mental health services for persons with serious mental illness. Psychiatr Serv 2005; 56: 324–331.

37.

37. Faulkner

Soundy

Lloyd

. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003; 108: 324–332.

38.

38. Centorrino

Wurtman

Duca

. Weight loss in overweight patients maintained on atypical antipsychotic agents. Int J Obes 2006; 30: 1011–1016.

39.

39. Aquila

Emanuel

. Interventions for weight gain in adults treated with novel antipsychotics. Prim Care Comp J Clin Psychiatry 2000; 2: 20–23.

40.

40. Menza

Vreeland

Minsky

Gara

Radler

Sakowitz

. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004; 65: 471–477.

41.

41. Pendlebury

Haddad

Dursun

. Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Hum Psychopharmacol 2005; 20: 447–448.

42.

42. Government of Canada. Canada's food guide to healthy eating (online) . Ottawa: Health Canada, 2005. [Accessed 25 May 2007.] Available from URL: http://www.hc-sc.gc.ca/hpfb-dgpsa/onpp-bppn/food_guide_rainbow_c.html .

43.

43. Airlie (VA) Consensus Conference. Standardization of anthropometric measurements. Champaign, IL: Human Kinetics Publishers, 1988.

44.

44. Couillard

, Després

, Lamarche

. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 2001; 21:1226–1232.

45.

45. Richterich

Dauwalder

. Determination of plasma glucose by hexokinase-glucose-6-phosphate dehydrogenase method. Schweiz Med Wochenschr 1971; 101: 615–618.

46.

46. Guy

. Clinical global impressions. ECDEU assessment manual for psychopharmacology, US Dept Health, Education and Welfare publication (ADM) 76–338. Rockville, MD: National Institute of Mental Health, 1976.

47.

47. Overall

Gorham

. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799–812.

48.

48. Manocchia

Bayliss

Connor

. SF-36 health survey annotated bibliographysecond edition. Health Assessment Lab, New England Medical Center, Boston, MA 1988; 1998.

49.

49. Reaven

. Role of insulin resistance in human disease. Diabetes 1988; 37: 1495–1507.

50.

50. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497.

51.

51. Galassi

Reynolds

. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812–819.

52.

52. Wilson

PWF

D'Agostino

Levy

Bélanger

Silbershatz

Kannel

. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.

53.

53. Basson

Kinon

Taylor

Szymanski

Gilmore

Tollefson

. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatr 2001; 62: 231–238.

54.

54. Craft

Landers

. The effect of exercise on clinical depression and depression resulting from mental illness: a meta-analysis. J Sports Exerc Psychol 1998; 20: 339–357.

55.

55. Lawlor

Hopker

. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. BMJ 2001; 322: 763–767.

56.

56. Faulkner

Biddle

. Exercise as an adjunct treatment for schizophrenia: a review of the literature. J Ment Health 1999; 8: 441–457.

57.

57. Martinsen

. The effects of exercise on mental health in clinical populations. European perspectives on exercise and sport psychology, Biddle

. Human Kinetics, StanningleyUK 1995; 185–211.

58.

58. O'Kelly

Piper

Kerber

Fowler

. Exercise groups in an insight-oriented, evening treatment program. Int J Group Psychother 1998; 48: 85–98.

59.

59. Brown

Birtwistle

Roe

Thomson

. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697–701.

60.

60. Davidson

Judd

Jolley

Hocking

Thomson

Hyland

. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 2001; 35: 196–202.

61.

61. Elmslie

Mann

Silverstone

Williams

Romans

. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001; 62: 486–491.

62.

62. Anthony

Cohen

Farkas

. Psychiatric rehabilitation. Center for Psychiatric Rehabilitation, Boston, MA 2002.

63.

63. Richardson

Faulkner

McDevitt

Skrinar

Hutchinson

Piette

. Integrating physical activity into mental health services for persons with serious mental illness. Psychiatr Serv 2005; 56: 324–331.

64.

64. Tremblay

Doucet

. Obesity: a disease or a biological adaptation?. Obes Rev 2000; 1: 27–35.

Management of Antipsychotic-Induced Weight Gain: Prospective Naturalistic Study of the Effectiveness of a Supervised Exercise Programme

Abstract

Keywords

Methods

Subjects

Project overview

Assessments

Anthropometric measurements

Biochemistry

Psychological assessments

Statistical analysis

Results

Participants

Changes in anthropometric variables

Changes in biochemistry

Changes in psychological measures

Discussion

Footnotes

Acknowledgements

References